NCRI 2016 | APOBEC enzymes contribute to cancer mutagenesis

Reuben Harris, PhD of University of Minnesota, Minneapolis, MN gives an overview of his talk focused on APOBEC enzymes. Dr Harris is interested in defining processes which cause cancer mutations in order to stop tumor evolvability. Existing therapies often fail due to drug-resistant mutations. APOBEC is a family of enzymes contributing to cancer mutagenesis. APOBEC signature mutations are defined as cytosine to thymine, or cytosine to guanine changes that happen within specific motifs, usually TCA, TCG or TCT. In some cancers, like cervical cancer it is 90% of all mutations. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.